Tesamorelin Half Life
Tesamorelin Half-Life
The short answer
Tesamorelin half-life is short: published pharmacokinetic data in the FDA label report a mean elimination half-life of roughly 26 to 38 minutes after repeated subcutaneous dosing, the lower end in healthy subjects and the upper end in the studied patient group (Tesamorelin FDA Prescribing Information).
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What is the half-life of tesamorelin?
The tesamorelin half-life is roughly 26 to 38 minutes after repeated subcutaneous dosing, per the pharmacokinetic data in the FDA label: about 26 minutes in healthy subjects and 38 minutes in the studied patient group after 14 consecutive days (Tesamorelin FDA Prescribing Information). That is a matter of minutes, not hours.
Tesamorelin is cleared quickly after subcutaneous injection. That is by design. It is a GHRH analog, so its role is to bind the GHRH receptor on the pituitary, prompt a release of growth hormone, and then leave the system. A compound built to imitate a natural pulse does not need to linger.
Why is the tesamorelin half-life so short?
The short half-life mirrors how the body's own GHRH works, in brief bursts rather than steady exposure.
Native GHRH is degraded rapidly in plasma. Tesamorelin adds a stabilizing modification that extends its life compared to unmodified GHRH, which is why it can be dosed once daily and still drive a measurable growth hormone response, but it remains a short-acting signaling molecule rather than a long-circulating drug. The point is the pulse, not persistent blood levels.
This is a different design goal from a molecule like CJC-1295, which was engineered for a much longer duration and sustained growth hormone and IGF-1 elevation (Teichman et al., 2006, Journal of Clinical Endocrinology and Metabolism, a CJC-1295 study cited here only as background contrast, not as tesamorelin PK). Tesamorelin sits at the short end of that spectrum.
How does a short half-life still produce a lasting effect?
The peptide clears in minutes, but the growth hormone and IGF-1 it releases circulate longer, so the biological signal outlives the drug.
Growth hormone secretagogues and GHRH analogs work indirectly. They do not act on fat or muscle directly. They ask the pituitary to release growth hormone, which then raises IGF-1 downstream (Falutz et al., 2007, New England Journal of Medicine). That cascade is why a molecule with a half-life of minutes can be linked to changes measured over weeks. In the tesamorelin literature, the meaningful endpoint was body composition over months, not plasma levels over hours.
Tesamorelin pharmacokinetic snapshot
The table summarizes what published sources report.
| Parameter | What sources report | Source |
|---|---|---|
| Drug class | Stabilized GHRH analog | Tesamorelin FDA Prescribing Information |
| Route studied | Subcutaneous injection | Falutz et al., 2007 |
| Plasma half-life | Roughly 26 to 38 minutes after repeated dosing | Tesamorelin FDA Prescribing Information |
| Mechanism | Stimulates pituitary GH release, raising IGF-1 | Falutz et al., 2007 |
| Trial dose reported | 2 mg daily | Falutz et al., 2007 |
| Reported effect | About 15 percent reduction in visceral adipose tissue | Falutz et al., 2007 |
What did the clinical trial actually report?
In the pivotal study, participants received 2 mg daily by subcutaneous injection, and the trial reported about a 15 percent reduction in visceral adipose tissue over the treatment period (Falutz et al., 2007, New England Journal of Medicine).
This is research-reported context, not a recommendation. The 2 mg figure describes what investigators used in a controlled trial with monitoring. It does not tell any individual what to take. The relevant takeaway for a half-life question is that a short-acting daily peptide produced a measurable body-composition change, which shows the effect tracks the downstream hormone response rather than plasma residence time.
How does tesamorelin compare to other GH-axis peptides?
Tesamorelin is short-acting by design, while other GH-axis compounds were built for longer exposure or oral availability.
- Tesamorelin: GHRH analog, plasma half-life of roughly 26 to 38 minutes, daily subcutaneous dosing in trials (Tesamorelin FDA Prescribing Information; Falutz et al., 2007).
- CJC-1295: engineered for extended duration and sustained GH and IGF-1 (Teichman et al., 2006).
- Ipamorelin: a selective growth hormone secretagogue that acts through a different receptor pathway (Raun et al., 1998).
- MK-677: an orally active secretagogue, but Nass et al., 2008 reported it raised fasting glucose and lowered insulin sensitivity, a reminder that GH-axis compounds carry metabolic trade-offs.
These act on the growth hormone axis through related but distinct routes, and their pharmacokinetics differ accordingly.
Keep reading
Related research and verification
Tesamorelin Half Life: FAQ
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
References
- US Food and Drug Administration. Egrifta (tesamorelin) Prescribing Information. Supports the reported mean elimination half-life of roughly 26 to 38 minutes after repeated subcutaneous dosing and the stabilized GHRH-analog drug class.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. N Engl J Med. 2007;357(23):2359 to 2370. doi:10.1056/NEJMoa072375 (PMID 18057338). The pivotal trial using 2 mg daily subcutaneous dosing that reported about a 15 percent visceral adipose tissue reduction.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006;91(3):799 to 805. doi:10.1210/jc.2005-1536 (PMID 16352683). Cited as background contrast for a GHRH analog engineered for longer duration and sustained GH and IGF-1.
- Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552 to 561. doi:10.1530/eje.0.1390552 (PMID 9849822). Cited as background for a selective GH secretagogue acting through a different receptor pathway.
- Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial. Ann Intern Med. 2008;149(9):601 to 611. doi:10.7326/0003-4819-149-9-200811040-00003 (PMID 18981485). Reports that the orally active secretagogue MK-677 raised fasting glucose and lowered insulin sensitivity.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.